全文获取类型
收费全文 | 1276755篇 |
免费 | 92485篇 |
国内免费 | 1987篇 |
专业分类
耳鼻咽喉 | 18185篇 |
儿科学 | 42257篇 |
妇产科学 | 37812篇 |
基础医学 | 186983篇 |
口腔科学 | 35381篇 |
临床医学 | 108104篇 |
内科学 | 251428篇 |
皮肤病学 | 26497篇 |
神经病学 | 99170篇 |
特种医学 | 49981篇 |
外国民族医学 | 366篇 |
外科学 | 197579篇 |
综合类 | 26514篇 |
现状与发展 | 1篇 |
一般理论 | 300篇 |
预防医学 | 92580篇 |
眼科学 | 29056篇 |
药学 | 97755篇 |
1篇 | |
中国医学 | 2496篇 |
肿瘤学 | 68781篇 |
出版年
2018年 | 11808篇 |
2015年 | 11610篇 |
2014年 | 15994篇 |
2013年 | 24343篇 |
2012年 | 33540篇 |
2011年 | 35935篇 |
2010年 | 21206篇 |
2009年 | 20013篇 |
2008年 | 34973篇 |
2007年 | 37940篇 |
2006年 | 38497篇 |
2005年 | 37791篇 |
2004年 | 36376篇 |
2003年 | 35366篇 |
2002年 | 34915篇 |
2001年 | 58093篇 |
2000年 | 59584篇 |
1999年 | 50686篇 |
1998年 | 14232篇 |
1997年 | 12809篇 |
1996年 | 13071篇 |
1995年 | 12345篇 |
1994年 | 11757篇 |
1993年 | 10860篇 |
1992年 | 40984篇 |
1991年 | 40358篇 |
1990年 | 39885篇 |
1989年 | 38706篇 |
1988年 | 36108篇 |
1987年 | 35349篇 |
1986年 | 33723篇 |
1985年 | 32134篇 |
1984年 | 23922篇 |
1983年 | 20818篇 |
1982年 | 12377篇 |
1981年 | 10927篇 |
1980年 | 10204篇 |
1979年 | 22635篇 |
1978年 | 15877篇 |
1977年 | 13729篇 |
1976年 | 12970篇 |
1975年 | 14201篇 |
1974年 | 16682篇 |
1973年 | 16076篇 |
1972年 | 15318篇 |
1971年 | 14229篇 |
1970年 | 13214篇 |
1969年 | 12731篇 |
1968年 | 11978篇 |
1967年 | 10478篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
161.
Eisen G. M. Eliakim R. Zaman A. 《世界核心医学期刊文摘》2006,2(5):27-28
背景与研究目的:静脉曲张破裂出血是肝硬化的一个主要并发症,与6周内20%的死亡率有关。目前国际指南推荐肝硬化患应常规行上消化道内镜检查(食管胃十二指肠内镜检查,EGD)来筛查是否有食管静脉曲张。新近出现的食管胶囊内镜在对胃食管反流和Barrett食管的研究中已经显示出准确的诊断效应。该研究比较胶囊内镜和EGD对肝硬化患食管胃底静脉曲张和门脉高压性胃病的检出率。患与方法:在3个中心进行了先导试验。有进行EGD临床指征的肝硬化患,在EGD检查后48h内用胶囊内镜来筛查或监视食管静脉曲张。研究采用盲法,即由1名事先不知道患病史和EGD检查结果的研究评估胶囊视频成像。结果:在32例纳入的患中,EGD和胶囊内镜检查发现有食管静脉曲张23例患。有1例患经胶囊内镜发现有轻度静脉曲张,但EGD未检出。胶囊内镜和EGD诊断食管静脉曲张和门脉高压性胃病的总体一致性分别为96.9%和90.6%。没有与胶囊内镜相关的不良事件。 相似文献
162.
Abstract Migraine without aura is typically considered a female condition. The purpose of this study was to determine if there have
been any changes in the female-to-male ratio of the disease over time. We included in the study all patients with migraine
without aura (n=3457) referred to the Parma University Headache Centre between 1976 and 1995. They were divided into subgroups with respect
to gender and year-range of onset of migraine (before 1960, in the 1960s, in the 1970s, in the 1980s, and between 1990 and
1995). Gender ratio ranged from 3.6:1 (in patients with onset before 1960) to 2.8:1 (in patients with onset in the 1980s),
with no statistically significant changes during the observation period. 相似文献
163.
Background
Hospital episode statistics (HES) is a UK national database for the National Health Service (NHS), now available online. The purpose of this study was to observe trends in ophthalmic operations performed during the period from 1998 to 2004, using this data. 相似文献164.
M B?ttner J Christoffel G Rimoldi W Wuttke 《Experimental and clinical endocrinology & diabetes》2006,114(2):82-90
The lack of estrogen during menopause is associated with various symptoms including osteoporosis, cardiovascular diseases, and menopausal symptoms. For many years, conventional hormone replacement therapy has been successfully used to treat these conditions. However, in light of recent studies that draw attention to potential hazards of conventional HRT, various attempts were undertaken to search for alternatives of classical HRT. Phytoestrogens are supposed to ameliorate various discomforts associated with menopause. Resveratrol (RES) is present in red wine, grapes and peanuts and has been implicated in cardioprotection and prevention of adverse side effects observed after regular HRT. As the pituitary-thyroid axis is a target of estrogen action, we first assessed the effects of E2 administration on thyroid hormone stimulating hormone releasing hormone (TRH)-induced thyroid stimulating hormone (TSH) secretion from pituitary cell cultures in vitro. Our data reveal that E2 treatment augments the TRH-induced TSH secretion. We furthermore designed a long-term study of three months to assess the effects of subcutaneous and oral administration of 17beta-estradiol (E2), as well as the actions of RES on the pituitary-thyroid axis in ovariectomized (OVX) female rats. Our results demonstrate that serum levels of 1.0 and 8.1 microM RES lead to a significant increase in total serum triiodthyronine (T3) levels. OVX induces TSHbeta mRNA in the adenohypohysis and E2 treatment attenuates this effect. Treatment of rats with subcutaneous implants of E2 does not affect the pituitary-thyroid axis, whereas orally applied E2 benzoate (E2B) increases plasma TSH and total thyroxine (T4) in OVX rats. In all animals, we could not detect changes in thyroid morphology as assessed by hematoxylin-eosin (HE) and Perjod-Acid Schiff's (PAS) staining. 相似文献
165.
166.
This review discusses treatment options for men with premature ejaculation (PE), a common sexual dysfunction characterized
by short ejaculatory latency, decreased sexual satisfaction, and distress. For a number of reasons, including embarrassment
and the belief that PE is a normal part of aging, that it has no effective treatment, or that it will resolve itself, few
men with PE seek treatment. Although several treatment options exist (eg, behavioral, cognitive, and sex therapy methods;
desensitizing drugs; off-label use of antidepressants, phosphodiesterase type 5 inhibitors, or à-blockers), the majority of
men with PE are not satisfied with their results. New pharmacologic drugs develped specifically for the treatment of PE are
undergoing evaluation in clinical trials. For example, recent clinical research studies have revealed on-demand administration
of one such drug, dapoxetine, which achieved significant improvements in ejaculatory latency, control over ejaculation, and
satisfaction with sexual intercourse. In addition, partners of men who received dapoxetine likewise reported improved satisfaction
with sexual intercourse. Future studies may reveal that integration of pharmacologic drugs with psychologic and/or behavioral
therapy techniques may be the optimal approach to the management of PE. PE is a treatable condition, and new drugs in development
may provide benefits over those available. 相似文献
167.
P F Plouin D L Clement H Boccalon J Dormandy I Durand-Zaleski G Fowkes L Norgren T Brown 《International angiology》2003,22(4):333-339
Atherosclerotic renal artery stenosis (ARAS) may cause hypertension, progressive renal failure, and recurrent pulmonary edema. It typically occurs in high risk patients with coexistent vascular disease elsewhere. Most patients with ARAS are likely to die from coronary heart disease or stroke before end-stage renal failure occurs. Recent controlled trials have shown that most patients undergoing angioplasty to treat renovascular hypertension still need antihypertensive agents 6 or 12 months after the procedure. Nevertheless, the number of antihypertensive agents required to control blood pressure adequately is lower following angioplasty than for medication alone. Trials assessing the value of revascularization for preserving renal function or preventing clinical events are only in the early recruitment phase. Revascularization should be undertaken in patients with ARAS and resistant hypertension or heart failure, and probably in those with rapidly deteriorating renal function or with an increase in plasma creatinine levels during angiotensin-converting enzyme inhibition. With or without revascularization, medical therapy using antihypertensive, hypolipidemic and antiplatelet agents is necessary in almost all cases. 相似文献
168.
M. Naumann A. Albanese F. Heinen G. Molenaers M. Relja 《European journal of neurology》2006,13(S4):35-40
Botulinum toxin serotype A (BoNT-A) has long heritage of use leading to confidence in its safety and efficacy. The application of BoNT-A does not lead to persistent histological changes in the nerve terminal or the target muscle. Clinical trials defined the safety and tolerability profile of BoNT-A across common therapeutic indications and showed an incidence of adverse events of approximately 25% in the BoNT-A-treated group compared with 15% in the control group. Focal weakness was the only adverse event to occur more often following BoNT-A treatment. Long-term BoNT-A administration has been assessed in various treatment settings, with the level and duration of BoNT-A efficacy response being maintained over repeated rounds of injection with no major safety concerns. The treatment of children with cerebral palsy often require long-term, repeated, multimuscle BoNT-A injections that lead to the administration of comparably higher toxin doses. Despite the high total body doses used, their distribution over multiple muscles and injection sites means that systemic side effects are rare. Recent formulation changes have reduced the incidence of antibody development following treatment with BOTOX® . These findings show long-term BoNT-A treatment to be both safe and efficacious for a wide variety of indications. 相似文献
169.
Is atrial fibrillation an inflammatory disorder? 总被引:2,自引:0,他引:2
I read with great interest the excellent review on the influenceof inflammation in the pathogenesis of atrial fibrillation (AF)by Boos 相似文献
170.